General form of registration statement for all companies including face-amount certificate companies

Note 8 - Net Loss Per Share (Tables)

v3.24.4
Note 8 - Net Loss Per Share (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Notes Tables    
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2024

   

2023

   

2024

   

2023

 

Net loss per share of common stock

                               

Numerator:

                               

Net loss

  $ (6,775 )   $ (2,832 )   $ (13,483 )   $ (1,848 )

Less cumulative preferred Series D dividends

    (194 )     (194 )     (582 )     (582 )

Net loss available to common shareholders – basic and diluted

  $ (6,969 )   $ (3,026 )   $ (14,065 )   $ (2,430 )
                                 

Denominator:

                               

Weighted-average number of shares outstanding used in computing net loss per share, basic and diluted

    5,720,009       5,720,009       5,720,009       5,720,009  
                                 

Net loss per share, basic and diluted

  $ (1.22 )   $ (0.53 )   $ (2.46 )   $ (0.42 )
   

Year Ended December 31,

 
   

2023

   

2022

 

Net income (loss) per share of common stock

               

Numerator:

               

Net income (loss) attributable to common stockholders

  $ 17,915     $ (27,552 )

Less: non-cumulative preferred Series C dividends

    (3,600 )      

Less: allocation of undistributed earnings to participating securities - preferred stock

    (10,431 )      

Net income (loss) attributable to common stockholders – basic and diluted

  $ 3,884     $ (27,552 )
                 

Denominator:

               

Weighted-average number of shares outstanding used in computing net income (loss) per share - basic

    5,720,009       5,718,926  

Effect of dilutive securities:

               

Stock options

    76,947        

Denominator for diluted net income (loss) per share – adjusted weighted average shares

    5,796,956       5,718,926  
                 

Net income (loss) per share, basic

  $ 0.68     $ (4.82 )

Net income (loss) per share, diluted

  $ 0.67     $ (4.82 )
Pieris Pharmaceuticals, Inc. [Member]    
Notes Tables    
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2024

   

2023

   

2024

   

2023

 

Net loss

  $ (2,887 )   $ (10,752 )   $ (11,369 )   $ (19,959 )

Basic weighted average common shares outstanding

    1,320       1,236       1,285       1,089  

Diluted weighted average common shares outstanding

    1,320       1,236       1,285       1,089  

Basic net loss per share

  $ (2.19 )   $ (8.70 )   $ (8.84 )   $ (18.33 )

Diluted net loss per share

  $ (2.19 )   $ (8.70 )   $ (8.84 )   $ (18.33 )